[en] We investigated the prevalence of human papillomavirus (HPV) in a clinical series of 72 patients with head and neck squamous cell carcinoma (HNSCC) using a retrospective and prospective study design. The majority of patients were smokers and/or drinkers and were treated with concomitant chemoradiotherapy (CCR). Furthermore, we assessed the impact of HPV positivity on the response to CCR. Paraffin-embedded samples from HNSCC patients (n=72) were evaluated for the presence of HPV DNA using both GP5+/GP6+ consensus PCR and type-specific E6/E7 PCR to detect HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67 and 68. The type-specific E6/E7 PCR demonstrated that 20 out of 69 HNSCC patients (29%) presented with high-risk (HR) HPV types and that 5 of the 69 HNSCC patients (7%) presented with low-risk (LR) HPV types. Using the GP5+/GP6+ PCR, we observed that the rate of response was statistically lower in the HPV+ group (P=0.02). Concerning patient outcomes in terms of recurrence and survival, we observed that the prognosis was poorer for HPV+ patients. We showed for the first time that patients with HPV+ HNSCC present with a worse prognosis after CCR. This observation highlights the need for prospective studies with large numbers of patients and a detailed history of tobacco and alcohol consumption before validating HPV as a marker of prognosis following CCR.
Disciplines :
Oncology
Author, co-author :
Duray, Anaelle
Descamps, Geraldine
Decaestecker, Christine
Sirtaine, Nicolas
Gilles, Andre
Khalife, Mohamad
Chantrain, Gilbert
Depuydt, Christophe E.
Delvenne, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Saussez, Sven
Language :
English
Title :
Human papillomavirus predicts the outcome following concomitant chemoradiotherapy in patients with head and neck squamous cell carcinomas.
World Health Organization: International Agency for Research on Cancer. Globocan, 2008. Available from: http://globocan.iarc.fr/.
Grandis JR, Pietenpol JA, Greenberger JS, Pelroy RA and Mohla S: Head and neck cancer: meeting summary and research opportunities. Cancer Res 64: 8126-8129, 2004. (Pubitemid 39446952)
Shah JP and Patel SG: Head and Neck Surgery and Oncology. 3rd edition. Mosby, New York, pp 232-236, 352, 2003.
Forastiere AA and Trotti A: Radiotherapy and concurrent chemotherapy: a strategy that improves locoregional control and survival in oropharyngeal cancer. J Natl Cancer Inst 91: 2065-2066, 1999. (Pubitemid 30019565)
Denis F, Garaud P, Bardet E, et al: Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22: 69-76, 2004. (Pubitemid 41095116)
Stenson KM, Kunnavakkam R, Cohen EE, et al: Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope 120: 93-99, 2010.
Milano MT, Vokes EE, Kao J, et al: Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol 28: 1141-1151, 2006.
Hu M, Ampil F, Clark C, Sonavane K, Caldito G and Nathan CA: Comorbid predictors of poor response to chemoradiotherapy for laryngeal squamous cell carcinoma. Laryngoscope 122: 565-571, 2012.
Sturgis EM and Cinciripini PM: Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 110: 1429-1435, 2007. (Pubitemid 47463055)
Dahlstrand H, Nasman A, Romanitan M, Lindquist D, Ramqvist T and Dalianis T: Human papillomavirus accounts both for increased incidence and better prognosis in tonsillar cancer. Anticancer Res 28: 1133-1138, 2008. (Pubitemid 351578850)
Reimers N, Kasper HU, Weissenborn SJ, et al: Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 120: 1731-1738, 2007. (Pubitemid 46399359)
Kumar B, Cordell KG, Lee JS, et al: Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat Oncol Biol Phys 69: 109-111, 2007.
Rischin D, Young RJ, Fisher R, et al: Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 28: 4142-4148, 2010.
Lill C, Kornek G, Bachtiary B, et al: Survival of patients with HPV-positive oropharyngeal cancer after radiochemotherapy is significantly enhanced. Wien Klin Wochenschr 123: 215-221, 2011.
Hong AM, Dobbins TA, Lee CS, et al: Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer 103: 1510-1517, 2010.
Sedaghat AR, Zhang Z, Begum S, et al: Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. Laryngoscope 119: 1542-1549, 2009.
Chung YL, Lee MY, Horng CF, et al: Use of combined molecular biomarkers for prediction of clinical outcomes in locally advanced tonsillar cancers treated with chemoradiotherapy alone. Head Neck 31: 9-20, 2009.
Nichols AC, Faquin WC, Westra WH, et al: HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg 140: 228-234, 2009.
de Jong MC, Pramana J, Knegjens JL, et al: HPV and high-risk gene expression profiles predict response to chemoradiotherapy in head and neck cancer, independent of clinical factors. Radiother Oncol 95: 365-370, 2010.
Fallai C, Perrone F, Licitra L, et al: Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status. Int J Radiat Oncol Biol Phys 75: 1053-1059, 2009.
Pim D, Collins M and Banks L: Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene 7: 27-32, 1992.
Depuydt CE, Benoy IH, Bailleul EJ, Vandepitte J, Vereecken AJ and Bogers JJ: Improved endocervical sampling and HPV viral load detection by Cervex-Brush Combi. Cytopathology 17: 374-381, 2006. (Pubitemid 44808532)
Depuydt CE, Boulet GA, Horvath CA, Benoy IH, Vereecken AJ and Bogers JJ: Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J Cell Mol Med 11: 881-891, 2007. (Pubitemid 47313308)
Arbyn M, Benoy I, Simoens C, Bogers J, Beutels P and Depuydt C: Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Prev 18: 321-330, 2009.
Filleul O, Preillon J, Crompot E, Lechien J and Saussez S: Incidence of head and neck cancers in Belgium: comparison with worldwide and French data. Bulletin du Cancer 98: 1173-1183, 2011.
Saussez S: Cancer of the upper aero-digestive tract: elevated incidence in Belgium, new risk factors and therapeutic perspectives. Bull Mem Acad R Med Belg 165: 453-461, 2010.
Duray A, Descamps G, Decaestecker C, et al: Human papillomavirus DNA strongly correlates with a poorer prognosis in oral cavity carcinoma. Laryngoscope 122: 1558-1565, 2012.
Rosenquist K, Wennerberg J, Annertz K, et al: Recurrence in patients with oral and oropharyngeal squamous cell carcinoma: human papillomavirus and other risk factors. Acta Otolaryngol 127: 980-987, 2007. (Pubitemid 47345810)
Hansson BG, Rosenquist K, Antonsson A, et al: Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. Acta Otolaryngol 125: 1337-1344, 2005. (Pubitemid 41722001)
Clayman GL, Stewart MG, Weber RS, el-Naggar AK and Grimm EA: Human papillomavirus in laryngeal and hypopharyngeal carcinomas. Relationship to survival. Arch Otolaryngol 120: 743-748, 1994. (Pubitemid 24217588)
Giskes K, Kunst AE, Benach J, et al: Trends in smoking behavior between 1985 and 2000 in nine European countries by education. J Epidemiol Community Health 59: 395-401, 2005. (Pubitemid 40559202)
Stanley MA: Immune responses to human papillomaviruses. Indian J Med Res 130: 266-276, 2009.
Hasan UA, Bates E, Takeshita F, et al: TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178: 3186-3197, 2007. (Pubitemid 46333201)
Lepique AP, Daghastanli KR, Cuccovia IM and Villa LL: HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res 15: 4391-4400, 2009.
Stanley MA: Immune responses to human papillomavirus. Vaccine 24: 16-22, 2006.
Tung YC, Lin KH, Chu PY, Hsu CC and Kuo WR: Detection of human papillomavirus and Epstein Barr virus DNA in nasopharyngeal carcinoma by polymerase chain reaction. Kaohsiung J Med Sci 15: 256-262, 1999.
Moscicki AB, Hills N, Shiboski S, et al: Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285: 2995-3002, 2001. (Pubitemid 32550118)
Kreimer AR, Alberg AJ, Daniel R, et al: Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis 189: 686-698, 2004. (Pubitemid 38270923)
